Valuation: Micromedic Technologies Ltd

Market Cap 26.25M 0 8.78M 7.52M 7.04M 6.44M 12.09M 840M 12.25M 83.16M 32.43M 422M 32.98M 32.26M 1.4B P/E 2023
-2.52x
P/E 2024 -7.86x
Enterprise Value 26.21M 0 8.77M 7.51M 7.03M 6.43M 12.07M 839M 12.23M 83.02M 32.38M 421M 32.92M 32.21M 1.39B EV / Sales 2023
-
EV / Sales 2024 57.4x
Free-Float
30.21%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 42 12/08/2020
Director of Finance/CFO 63 10/07/2022
General Counsel 55 12/08/2020
Director TitleAgeSince
Chairman 87 21/11/2011
Director/Board Member 76 13/10/2014
Director/Board Member 71 12/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
+5.37%+92.48% - - 4.4M
+2.16%+5.05%+105.78%+303.57% 4.15B
-7.79%+18.77%+226.38%+31.80% 3.76B
+1.24%+2.57%+43.76%+63.68% 3.4B
+3.45%+7.26%+288.57%+463.92% 2.51B
-3.61%+3.84%-18.47%-20.90% 2.41B
-0.88%+16.87%+27.81% - 1.48B
+4.22%+51.58%+261.51%-17.56% 1.29B
-2.40%-5.13%+17.99%+39.91% 1B
-2.72%-2.82%-36.21%-1.66% 552M
Average -0.10%+11.21%+101.90%+107.84% 2.28B
Weighted average by Cap. -0.77%+10.62%+121.38%+143.05%

Financials

2023 2024
Net sales 876K 0 293K 251K 235K 215K 404K 28.04M 409K 2.78M 1.08M 14.09M 1.1M 1.08M 46.59M 413K 0 138K 118K 111K 101K 190K 13.22M 193K 1.31M 510K 6.64M 519K 508K 21.97M
Net income -3.88M -0 -1.3M -1.11M -1.04M -952K -1.79M -124M -1.81M -12.29M -4.79M -62.37M -4.87M -4.77M -206M -3.28M -0 -1.1M -941K -880K -806K -1.51M -105M -1.53M -10.4M -4.06M -52.79M -4.12M -4.03M -175M
Net Debt -101K -0 -33.79K -28.94K -27.08K -24.79K -46.53K -3.23M -47.14K -320K -125K -1.62M -127K -124K -5.37M -43K -0 -14.39K -12.32K -11.53K -10.55K -19.81K -1.38M -20.07K -136K -53.12K -691K -54.02K -52.84K -2.29M
Logo Micromedic Technologies Ltd
Nextage Therapeutics Ltd, formerly known asMicromedic Technologies Ltd,is an Israel-based company engaged in the development and commercialization of cancer diagnostic products. Its portfolio includes a range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment. Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products. Micromedic operates through strategic collaborations and in-licensing from scientific institutes world-wide as well as in-house based research.
Employees
-